Is the single use of 
Method Twenty-four patients (25 eyes) with a mean age of 63.7 ± 14.7 years (range 27-86 years) and a history of one or more risk factors (age <50 years, more than 3 years on topical medication, a previous failed filter, previous cataract surgery, uveitis, neovascular glaucoma) underwent trabeculectomy with the intraoperative application of 5FU on a sponge (25 mglml) for 5 min. The average follow-up was 10.1 ± 5.5 months.
Results The mean pre-operative intraocular pressure (lOP) was 24.7 ± 6.2 mmHg and the mean post-operative lOP was 13.9 ± 3.5 mmHg. Success, defined as an lOP within desired target levels for a particular eye, in the presence of a functioning filter, without supplementary medical therapy, was achieved in 56.5% of cases. 
Conclusions

I I
We present our initial experience with the single intraoperative application of 5FU in patients with low / moderate-to high-risk characteristics for filtering surgery failure.
Materials and methods
Twenty-four consecutive patients (25 eyes) were recruited for this study between 1993 and 1995 (both the eyes of patient 8 were included).
Inclusion criteria were uncontrolled glaucoma on maximally tolerated medical therapy and low / moderate-to high-risk factors for failure of filtering surgery. Exclusion criteria were previous filtering surgery with the use of an antimetabolite or post-operative 5FU injections.
The risk factors are outlined in Table 1 . A stratification of risk factors into high-risk (major) and low-risk (minor) was chosen as it is patients in the high-risk group who have a poor prognosis for successful filtering surgery. with a 2 mm X 2 mm block of trabecular tissue excised
High risk: Presence of any of the major factors.
freehand. A peripheral iridectomy was performed and the scleral flap closed with an average of two 10-0 nylon A trabeculectomy was performed (by P. W. and J. M.)
interrupted sutures depending on the number necessary as described elsewhere,13 with a limbal-based to keep the anterior chamber formed. The conjunctival conjunctival flap and a scleral flap 4 mm X 4 mm in size.
incision was closed with an 8-0 continuous Vicryl suture. The 5FU (David Bull Laboratories, Warwick, UK) was A subconjunctival injection of betamethasone and cefuroxime
4,2 months and 6 months post-operatively. Additional visits were dictated by the condition of the patient. The post-operative regimen of drops included a steroid antibiotic combination (dexamethasone, neomycin and polymixin B sulphate) for 2 weeks followed by a tapering dose of dexamethasone for 12 weeks post-operatively.
Success was defined as complete or qualified.
Complete success was an intraocular pressure that was considered safe for that particular optic nerve (target pressure), without supplementary medical therapy, in the presence of a functioning filter. Qualified success was as above but with the help of supplementary medical therapy.
Results
Of the 24 patients, one was lost to follow-up (patient 14) and another was excluded as he received supplementary were complete successes; a further eye was a qualified success. The mean duration of follow-up was 10.1 ::':: 5.5 months (range 3-24 months). The patients maintained the level of pre-operative visual acuity and visual fields throughout follow-up. The post-operative complications included a shallow anterior chamber (AC) in one patient, a flat AC without keratolenticular contact, wound leak in two patients, early hypotony in two patients, and <2 mm hyphaemas in two patients. All these complications resolved with conservative management (Table 3) .
Both the patients in the low-risk category were successes; one patient (1 of 2 eyes) in the moderate-risk group failed. Nine eyes (9 of 19 eyes) in the high-risk group were successful (47.3%). The Kaplan-Meier survival estimates demonstrate the probability of successful lOP control after intraoperative use of 5FU during a trabeculectomy (Fig. 1) . The introduction of post-operative subconjunctival injections of 5FU has improved the success rate of filtering surgery in high-risk patients.12.14-16 The optimal route of administration, however, seems to be a single intraoperative application of 5FU on a sponge. It offers several advantages over the injections, in that it avoids multiple post-operative visits, there is no pain associated with its application, the corneal epithelium is unaffected and wound leaks are uncommon. In addition the drug is delivered at the site where it is required to offset the fibrosis associated with failure. The drawback of a single intraoperative application of 5FU on a sponge is that the dose cannot be measured or titratedY
The initial results reported by Lanigan et al.l1 were encouraging, with a success rate of 91% (100% if the results of only the low-to moderate-risk category were considered) with a limited follow-up (of 3-9 months). In the first year of follow-up of the Fluorouracil Filtering Surgery Study (FFSS) there was a 73% success rate in patients with moderate-to high-risk characteristics, compared with a 50% success rate for the control group. 14 The success rate in the group of patients presented here was 56.5% (60.8% qualified successes were included) over a follow-up ranging from 3 to 24 months (mean 10.1 ::':: 5.5 months). If our two low-risk category patients were excluded the success rate was 47.3% (9/19) . This is similar to the controls of the FFSS group with comparable lengths of follow-up. This trend from our study seems to suggest that the single application of intraoperative 5FU offers no advantage in the moderate to high-risk category. The results are at odds with previous studies (Table 4) , which may be explained by the differing risk categories, different lengths of follow up, and differing criteria for success. Mora et aZY reported a success rate of 86.4%. The shortest length of follow-up was 2 months, the concentration of 5FU was 50 mg/ml and the majority of eyes received an average of 5.3 supplementary 5FU injections post-operatively, which may explain the improved success rate.
In a black population from Ghana, Singh et al.18 reported a success rate of 73% (lOP <21 mmHg). This differs from our population group, in addition to the fact that the concentration of 5FU was 50 mg/ml and the technique of application differed slightly.
Bell et aZ.19 reported a success rate of 80% on or off supplementary medical therapy, with no difference between the high-or low-risk groups, with a mean follow-up of 24 months. If only the complete successes were considered, the percentage dropped to 48.8%. Amongst the complete successes there were 8 of 11 patients (73% success rate) in the low / moderate-risk groups (our classification) and 14 of 34 (41.1% success rate) in the high-risk category. The latter figures do correlate with the figures in our high-risk category. This study differs from ours in that the authors used post operative 5FU injections if there were signs of bleb failure, and the technique of application was slightly different in that the 5FU was applied before the scleral dissection.
The 5 year follow-up of the FFSS recently reported a further drop-off in the success rate, and at the end of the study period 49% of eyes maintained successful filters compared with 26% in the control group. 16 It is possible that the percentage of successful cases in our series will fall with a longer follow-up.
Though not comparable in terms of mode of 5FU application, when the results for the first year of the FFSS are compared with those of our study, it would seem reasonable to suggest that the dose delivered by a single intraoperative application of 5FU on a sponge is insufficient to improve the success rate of filtering surgery in patients who present with high-risk characteristics.
It is not known whether a higher concentration of the drug (50 mg/ml; not commerically available in the UK) would offer any advantage over the 25 mg / ml concentration. Khaw et al. 20 (Table 4) , the conclusion one could draw from them and our study is that the single use of 5FU intraoperatively may prolong the survival of filtering procedures in patients with either no risk factors or low to moderate risk factors.
The use of intraoperative 5FU at best achieves a reversible delay of fibroblast proliferation; animal studies suggest that this may be as short as 1 week.22 Hence the patients with high-risk characteristics may require a 'fibrocidal' antimetabolite such as mitomycin C23 or prolonged administration of 5FU injections in addition to the dose applied intraoperatively on a sponge. Smith et al. 24 reported a success rate of 93% in a mixed group of patients who received adjunctive 5FU on a sponge together with post-operative injections; however, this regime negates some of the advantages offered by a single intraoperative application, except that the number of post-operative injections may be reduced.
Conclusion
This small group of patients with a reasonable follow-up period demonstrate a trend that a single intraoperative application of 5FU on a sponge is insufficient alone to enhance the success of filtering surgery in patients with high-risk characteristics.
